Treat to target in Crohn's disease: A practical guide for clinicians

被引:5
|
作者
Srinivasan, Ashish R. [1 ,2 ,3 ,4 ]
机构
[1] Austin Hlth, Dept Gastroenterol, Melbourne, Vic 3083, Australia
[2] Eastern Hlth, Dept Gastroenterol, Melbourne, Vic 3128, Australia
[3] Univ Melbourne, Dept Med, Melbourne, Vic 3052, Australia
[4] Austin Hlth, Dept Gastroenterol, 145 Studley Rd,Heidelberg, Melbourne, Vic 3083, Australia
关键词
Treat to target; Inflammatory bowel disease; Crohn's disease; Treatment targets; Endoscopic remission; Transmural healing; Time to response; Intestinal ultrasound; INFLAMMATORY-BOWEL-DISEASE; VEDOLIZUMAB INDUCTION THERAPY; REPORTED OUTCOME MEASURES; FECAL CALPROTECTIN; TO-TARGET; MAINTENANCE THERAPY; LONG-TERM; INTESTINAL ULTRASOUND; COMPUTED-TOMOGRAPHY; ENDOSCOPIC SCORE;
D O I
10.3748/wjg.v30.i1.50
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
A treat-to-target (T2T) approach applies the principles of early intervention and tight disease control to optimise long-term outcomes in Crohn's disease. The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)-II guidelines specify short, intermediate, and long-term treatment goals, documenting specific treatment targets to be achieved at each of these timepoints. Scheduled appraisal of Crohn's disease activity against pre-defined treatment targets at these timepoints remains central to determining whether current therapy should be continued or modified. Consensus treatment targets in Crohn's disease comprise combination clinical and patient-reported outcome remission, in conjunction with biomarker normalisation and endoscopic healing. Although the STRIDE-II guidelines endorse the pursuit of endoscopic healing, clinicians must consider that this may not always be appropriate, acceptable, or achievable in all patients. This underscores the need to engage patients at the outset in an effort to personalise care and individualise treatment targets. The use of non-invasive biomarkers such as faecal calprotectin in conjunction with cross-sectional imaging techniques, particularly intestinal ultrasound, holds great promise; as do emerging treatment targets such as transmural healing. Two randomised clinical trials, namely, CALM and STARDUST, have evaluated the efficacy of a T2T approach in achieving endoscopic endpoints in patients with Crohn's disease. Findings from these studies reflect that patient subgroups and Crohn's disease characteristics likely to benefit most from a T2T approach, remain to be clarified. Moreover, outside of clinical trials, data pertaining to the real-world effectiveness of a T2T approach remains scare, highlighting the need for pragmatic real-world studies. Despite the obvious promise of a T2T approach, a lack of guidance to support its integration into real-world clinical practice has the potential to limit its uptake. This highlights the need to describe strategies, processes, and models of care capable of supporting the integration and execution of a T2T approach in real-world clinical practice. Hence, this review seeks to examine the current and emerging literature to provide clinicians with practical guidance on how to incorporate the principles of T2T into routine clinical practice for the management of Crohn's disease.
引用
收藏
页码:50 / 69
页数:21
相关论文
共 50 条
  • [1] Treat to target with ustekinumab for Crohn's disease
    Ungaro, Ryan C.
    Colombel, Jean-Frederic
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 276 - 277
  • [2] Missing the Target to Treat in Crohn's Disease
    Van Kruiningen, Herbert J.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (13) : 2381 - 2382
  • [3] Infliximab in the treatment of Crohn's disease: A user's guide for clinicians
    Sandborn, WJ
    Hanauer, SB
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (12): : 2962 - 2972
  • [4] Objective evaluation for treat to target in Crohn's disease
    Takenaka, Kento
    Kitazume, Yoshio
    Fujii, Toshimitsu
    Tsuchiya, Kiichiro
    Watanabe, Mamoru
    Ohtsuka, Kazuo
    [J]. JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 579 - 587
  • [5] Missing the Target to Treat in Crohn's Disease Reply
    Sandborn, William J.
    Bouguen, Guillaume
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (13) : 2382 - 2382
  • [6] Objective evaluation for treat to target in Crohn’s disease
    Kento Takenaka
    Yoshio Kitazume
    Toshimitsu Fujii
    Kiichiro Tsuchiya
    Mamoru Watanabe
    Kazuo Ohtsuka
    [J]. Journal of Gastroenterology, 2020, 55 : 579 - 587
  • [7] Treat-to-target and sequencing therapies in Crohn's disease
    Garcia, Nicole M.
    Cohen, Nathaniel A.
    Rubin, David T.
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2022, 10 (10) : 1121 - 1128
  • [8] Practical Management Guide for Clinicians Who Treat Patients with Amiodarone
    Epstein, Andrew E.
    Olshansky, Brian
    Naccarelli, Gerald V.
    Kennedy, John I., Jr.
    Murphy, Elizabeth J.
    Goldschlager, Nora
    [J]. AMERICAN JOURNAL OF MEDICINE, 2016, 129 (05): : 468 - 475
  • [9] A practical guide for clinicians who treat patients with amiodarone: 2007
    Goldschlager, Nora
    Epstein, Andrew E.
    Naccarelli, Gerald V.
    Olshansky, Brian
    Singh, Bramah
    Collard, Harold R.
    Murphy, Elizabeth
    [J]. HEART RHYTHM, 2007, 4 (09) : 1250 - 1259
  • [10] Memory Loss, Alzheimer's Disease, and Dementia: A Practical Guide for Clinicians
    Kirshner, Howard S.
    Budson, Andrew E.
    Solomon, Paul R.
    [J]. COGNITIVE AND BEHAVIORAL NEUROLOGY, 2022, 35 (04) : 298 - 299